Daily Archives: March 11, 2020

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

  • Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University
  • Phase 2b clinical efficacy study of experimental malaria vaccine with Matrix‑M nearing completion in Burkina Faso

GAITHERSBURG, Md., March 11, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII) today announced a commercial license agreement for the use of Novavax’ proprietary Matrix-M™ vaccine adjuvant with SII’s malaria vaccine candidate. SII licensed the R21 malaria vaccine, which targets the most severe plasmodium falciparum-induced malaria disease, from the Jenner Institute at Oxford University in 2017. Matrix-M is a key component in the malaria vaccine candidate, currently in a Phase 2b clinical trial sponsored by the Jenner Institute, with top-line data expected to be reported in the second quarter of 2020.

Under the terms of the agreement, SII is granted rights to use Matrix-M in the vaccine in regions where the disease is endemic and will pay Novavax royalties on its market sales of the vaccine. Matrix-M will be manufactured and supplied to SII by Novavax AB, a wholly-owned subsidiary of Novavax based in Uppsala, Sweden.

In addition, as part of the arrangement, Novavax has gained the rights to sell and distribute the SII-manufactured vaccine in high-income countries, primarily in the travelers and military vaccine markets.

Dr. Adrian Hill, director of the Jenner Institute, is leading the clinical studies of the experimental vaccine, which was created using the R21 malaria antigen combined with Matrix-M. He commented, “It has proven very challenging to develop a vaccine against malaria and many different approaches have been tested. After a thorough evaluation of several adjuvants pre-clinically many years ago, we selected Matrix-M for this program based on the strong immune responses elicited in those preclinical studies. Multiple clinical trials sponsored by the Jenner Institute have now confirmed these immunogenicity results. The current Phase 2b efficacy trial represents an important opportunity to test the efficacy of a malaria vaccine using the potent Matrix-M adjuvant in infants in an endemic setting.”

“Novavax’ next-generation adjuvant, Matrix-M, is an impressive and critical component in this much-needed malaria vaccine,” said Adar Poonawalla, Chief Executive Officer of Serum Institute of India. “This will be an important long-term partnership in advancing an innovative potential malaria vaccine and while we have much work to do, this marks a key step forward.”

“As the world’s largest vaccine producer in terms of doses delivered, Serum Institute of India is the ideal partner to ensure that an improved malaria vaccine ultimately reaches the many millions of individuals at risk in areas where malaria is endemic,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “This agreement highlights our mutual confidence in Matrix-M’s ability to induce a strong immune response that will ultimately increase vaccine effectiveness.”

About Malaria

Malaria is a serious and sometimes fatal disease caused by at least four different parasites that are found on certain types of mosquitos. Plasmodium falciparum, the most severe of these parasites, causes the type of malaria that is most likely to result in severe infections and, if not promptly treated, can lead to death. There are approximately 2,000 annual cases of malaria diagnosed in the U.S.; the vast majority of which are in travelers and immigrants returning from endemic parts of the world where malaria transmission occurs.

Globally, the World Health Organization estimated that in 2018, over 200 million clinical cases of malaria occurred, resulting in over 400,000 deaths, mostly children in Africa.1 Globally, malaria is the one of the leading causes of death in children younger than age five years.

About Matrix-M™

Matrix-M™ is Novavax’ next-generation saponin-based adjuvant, powered by a novel formulation that provides a potent and well-tolerated adjuvant effect. Saponins are steroid or triterpenoid glycosides, which occur in many plant species. In Matrix-M, purified saponin fractions are mixed with synthetic cholesterol and a phospholipid to form stable particles than can be readily formulated with a variety of vaccine antigens. Saponin-based adjuvants act in part by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in the local lymph nodes. Matrix-M has the ability to stimulate cell-mediated immunity as well as to enhance antibody production; and importantly, when facing rapidly emerging diseases such as those caused by coronaviruses, Ebola virus or pandemic influenza, they can allow immune responses to be achieved with much lower doses of antigen, known as “dose-sparing.” Matrix-M also increases the opportunity for longer-lasting immunity, which may reduce the number of vaccinations needed to gain optimal protection.

Novavax’ past experience with saponin-based adjuvants in both animals and humans indicates that, like all adjuvants, they increase the local reaction at the injection site. However, those local reactions are transient and there is no evidence of longer-term adverse effects. Matrix-M has been evaluated in several Novavax vaccine candidates, including Novavax’ Phase 3 NanoFlu™ vaccine for influenza in older adults, and is expected to be included in Novavax’ COVID-19 vaccine candidate, which is expected to go into clinical trials in spring of 2020.

1 WHO 2019 World Malaria Report https://www.who.int/publications-detail/world-malaria-report-2019

About Novavax

Novavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, is currently in a pivotal Phase 3 clinical trial to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine to demonstrate efficacy in a Phase 3 clinical trial. Novavax recently initiated development of a vaccine program against COVID-19. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

About Serum Institute of India

Serum Institute of India Pvt. Ltd. was founded in 1966 by Dr. Cyrus Poonawalla with a mission of manufacturing life-saving immuno-biologics. Serum is the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses). It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by Serum are accredited by the World Health Organization, Geneva and are being used in approximately 170 countries across the globe.

Serum is ranked as India’s No. 1 biotechnology company, manufacturing highly specialized lifesaving biologics like vaccines using cutting edge genetic and cell-based technologies, antisera and other medical specialties.

The philanthropic philosophy of Serum continues with its work on newer vaccines and biologicals.

Learn more about Serum Institute of India at https://www.seruminstitute.com/.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2018, and Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.


Novavax, Inc.
Erika Trahan

John Woolford

Brandzone/Speak Life Science
Amy Speak
(617) 420-2461


Jackson Memorial Hospital gives Philips Enterprise Monitoring as a Service model high marks for satisfaction and efficiency

March 11, 2020

Nursing staff gives new solution 90%* staff satisfaction rating and new transport process 94%*; workflow improvements help flagship site for leading health system deliver on Quadruple Aim

Amsterdam, Netherlands and Miami, FL, U.S. – Royal Philips (NYSE: PHG, AEX: PHIA), a leading health technology company, and Jackson Health System, one of the nation’s largest public health systems, today announced new findings from a performance improvement evaluation at Jackson Memorial Hospital. The evaluation looked at the impact of its new Enterprise Monitoring as a Service (EMaaS) model six months after its deployment as part of a groundbreaking Philips partnership. Nursing staff gave the new model a 90%* satisfaction rating, up from 8%* prior to the new system [1] – an 82% improvement. The hospital also estimates it will save 13,331 staff hours from workflow improvement and automation of manual tasks. Moreover, the new patient transport process has reduced the time it takes to connect a patient to a transport monitor from 5 minutes to 3.9 seconds – saving staff more than 4 minutes and 56 seconds per patient and helping to earn a 94%* overall satisfaction rating from nursing staff.

Jackson Memorial Hospital, a nonprofit tertiary care teaching hospital in Miami, is the centerpiece of Jackson Health System. The 1,550 licensed bed hospital is focused on continuous improvement, including standardization of patient monitoring solutions for all acuity levels and settings, as well as improving accuracy of data. By adopting the EMaaS model, Jackson can move away from traditional capital outlay models, which can require buying the monitoring technology, consumption-based engagement or paying for monitoring capacity per patient. Moreover, it will give the hospital better performance visibility, utilization transparency and other improvements across the enterprise.

“Standardizing Jackson Memorial’s patient monitoring has simplified the staffing and management of our Central Monitoring Unit,” said David Zambrana, the former CEO of Jackson Memorial Hospital and current EVP for Hospital Operations of Jackson Health System. “It has also simplified the work required to electronically send patient data to our Electronic Medical Records system, managing the network and interfaces over time. Our partnership provides the ongoing support and proactive management we want for a life-critical capability that we rely on 24/7*.”

The new Philips patient monitoring solution is also interoperable and automates clinical data sharing, which saves time by quickly making critical information – such as a patient’s vital signs – directly available to staff through the Electronic Medical Record (EMR) system. Moreover, Philips will continue to provide technical support, including helping Jackson to design solutions that seamlessly integrate with core IT systems such as the EMR. Philips will also help Jackson identify clinical workflow optimization opportunities, provide continuing education and assist with asset and data management.

“Forward thinking healthcare systems like Jackson want to achieve the Quadruple Aim and realize they need to move away from transactional relationships to true partnerships, both with their patients and their vendors, in order to provide quality care at a lower cost,” said Vitor Rocha, Chief Philips North America and member of the Executive Committee, Royal Philips. “Working together, we have developed the EMaaS model, which provides them with a state-of-the-art, scalable patient monitoring solution that reduces their per capita cost of care, while allowing them to improve the patient and staff experience. By automatically sharing vital patient information through the EMR, they are creating a more seamless experience, helping their staff to deliver the right care at the right time.”

*This data is exclusive to Jackson Memorial Hospital. Results from case studies are not predictive of results in other cases. Results in other cases may vary.

[1] 90% of the clinical team surveyed in critical care units indicated they were somewhat satisfied or highly satisfied when asked to rate their overall satisfaction with the current patient monitoring system at Jackson Memorial Hospital.

For further information, please contact:

Silvie Casanova
Philips North America
Tel: +1 781-879-0692
Email: Silvie.casanova@philips.com

Kathy O’Reilly
Philips Global Press Office
Tel: +1 978-221-8919
Email: Kathy.oreilly@philips.com

Jackson Health System

Jackson Health System is an integrated healthcare delivery network with more than 12,000 employees. It has been a central provider of medical services and healthcare leadership for residents of Miami-Dade County for more than a century. The centerpiece of Jackson Health System is Jackson Memorial Hospital, a world-class regional center of specialized care that functions as the primary teaching hospital for the University of Miami Leonard M. Miller School of Medicine. Jackson’s robust network also includes two community hospitals, a children’s hospital, a rehabilitation hospital, a behavioral health hospital, a network of urgent care centers, two long-term care nursing facilities, and both primary and specialty care centers across Miami-Dade County. The new Jackson West Medical Center campus is under development in the City of Doral, and will feature a 100-bed inpatient hospital, adult and pediatric emergency rooms and outpatient services. Owned and supported by the taxpayers of Miami-Dade County, Jackson is governed by Public Health Trust Board of Trustees under the auspices of the Miami-Dade County Mayor and Board of County Commissioners.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


The Graduate Management Admission Council Welcomes One of Portugal’s Leading Business and Economic Institutes

Newest Member Reflects the Importance of Globalization and Diversification in Graduate Management Education

RESTON, Va., March 11, 2020 (GLOBE NEWSWIRE) — The Graduate Management Admission Council™ (GMAC™), a global association of leading graduate business schools, today announced the addition of one of Portugal’s top business schools into its membership. The addition of Nova School of Business & Economics (Nova SBE), brings GMAC’s total membership to 229 institutions.

GMAC member schools go through an invitation-only process governed by the organization’s board of directors. Nominees then participate in a comprehensive application process that addresses the sustained commitments to supporting GMAC’s mission: providing the tools and information necessary for schools and talent to discover and evaluate each other.

“Nova SBE is committed to the constant improvement of competent and responsible management education,” said Professor Rita Campos Cunha, Deputy Dean, Pre-Experience Studies. “As a school, we are designed as an open platform, always seeking dialogue and an exchange of ideas and best practices with our colleagues. We believe that GMAC is an excellent convener of business schools from around the world to which we can contribute through our own experiences and know-how, while also benefiting from the shared experience of other member schools.”

“As business education evolves with the ever-changing pace of the global marketplace, institutions such as Nova School of Business & Economics understand the importance of innovation in how and what they are teaching tomorrow’s changemakers,” said Sangeet Chowfla, president and CEO of GMAC.

Nova SBE considers itself a community of world citizens. Sharing GMAC’s vision of diversity, the institution strives to stay at the forefront of innovation while preparing executives and entrepreneurs of tomorrow to contribute to a more open, sustainable, and inclusive world. Financial Times has ranked the school 22nd for its International Master’s in Management worldwide; 21st for its International Master’s in Finance worldwide; and among the top 30 Business Schools in Europe. Recently relocated to a new campus in Lisbon’s Carcavelos neighborhood, Nova SBE is eager to offer students a modern, interactive, and collaborative learning experience.

To be considered for membership in GMAC, schools complete an application process and must maintain a selective admissions process; offer a master’s program in business administration, management subjects or equivalent; and actively support GMAC’s mission and use the GMAT exam or other GMAC assessments as part of their admissions and enrollment processes. They also participate in GMAC governance, including voting on board elections and other matters that may come before the Council.

About GMAC
The Graduate Management Admission Council (GMAC) is a mission-driven association of leading graduate business schools worldwide. Founded in 1953, we are committed to creating solutions for business schools and candidates to better discover, evaluate and connect with each other. We work on behalf of the schools and the graduate management education community, and guide candidates on their journey to higher education, to ensure that no talent goes undiscovered.

GMAC provides world-class research, professional development opportunities and assessments for the graduate management education industry, designed to advance the art and science of admissions. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment, recognized by more than 7,000 programs worldwide. Other GMAC assessments include the NMAT by GMAC™ (NMAT™) exam, for entrance into graduate management programs in India, Nigeria, the Philippines, and South Africa, and the Executive Assessment (EA), which supports the admissions needs of more than 160 programs around the world.

Our flagship portal for graduate management education resources and information, www.mba.com, receives over 7 million visits a year and features the Program Finder matching tool and GMASS™ search service, a data-driven technology that helps connect candidates and business schools.  These platforms are part of GMAC Connect, a suite of services that help schools attract students through recruiting solutions that marry our market intelligence, data, reach and candidate touchpoints.

Subsidiaries of GMAC include UK-based online publishing company BusinessBecause, a content-rich destination that helps students identify the right-fit business schools during the critical consideration and selection phases of their journey, and The MBA Tour, which supports business schools’ global recruiting efforts by organizing business education-focused events around the world.

GMAC is a global organization with offices in China, India, Singapore, United Kingdom and the United States. To learn more about our work, please visit www.gmac.com.

About Nova SBE
Nova SBE is a leading school in the areas of Economics, Finance, and Management through its undergraduate, master’s, Ph.D., MBA, and Executive Education programs. It is on the list of the 30 best schools in Europe with about 3000 students from more than 70 different countries, with its programs recognized by the Financial Times. The school is a member of the CEMS since December 2007, and a member of the restricted group of international Triple Crown schools, being the only Portuguese school classified by Eduniversal as “Universal Business School” with five Eduniversal Palms. It was the first Portuguese business school to acquire international accreditations and worldwide recognition in higher education. The international vision of Nova SBE is also reflected in the adoption of English as the main teaching language. The current Dean is Prof. Dr. Daniel Traça (Ph.D., Columbia University), also a former student of the school (BSc Economics ’85).

Media contact:
Geoffrey Basye, Director of Media Relations, GMAC
+1 (703) 668-9799 or gbasye@gmac.com

Pomelo Selects Partnerize As Its Exclusive Partnership Automation Solution

Leading digital fashion retailer will leverage the Partnerize Platform to manage all of its revenue partnerships across its Southeast Asian trading region

BANGKOK, Thailand, March 11, 2020 (GLOBE NEWSWIRE) — Partnerize, the leader in partnership automation solutions for global brands, today announced that Pomelo, a leading digital fashion platform in Asia, has chosen the Partnerize Platform to accelerate growth as its exclusive partnership automation solution. The AI-powered Partnerize Partnership Automation Platform combines data-driven intelligence and industry-leading management tools that are essential to unlocking maximum ROI from partnerships.

Pomelo’s decision to choose Partnerize is part of a wider strategy to integrate a catalog of innovative technologies, enabling the fashion-technology company to develop a 360 view of their customers and optimize workflows.  In line with their omnichannel strategy, Pomelo leverages best-of-breed technology to establish a seamless customer experience and capture business insights. Pomelo will use the Partnerize Platform to increase partner-driven sales, ensure accurate traffic and revenue attribution, and expand its partner ecosystem with new partners that can drive outstanding scale.

“At Pomelo, our goal has always been to seamlessly connect the online and offline experience for our customers,” said Jean Thomas, CMO at Pomelo. “We’re confident that the Partnerize platform will allow us to achieve this while also enabling us to ramp up our marketing efforts in an efficient and scalable way.”

One key factor in the selection was the seamless Partnerize integration with Pomelo’s deep-linking and mobile measurement platform, Branch. The majority of Pomelo sales are made on mobile devices. Comprehensive mobile and cross-device tracking is an essential element of any performance marketing program to ensure that each partner is credited with all of the conversions it drives.

With the recent appointment of Anders Heikenfeldt as Chief Retail Officer, Pomelo will continue to drive retail expansion across Southeast Asia. The company plans to leverage the massive Partnerize ecosystem of partners in order to drive growth and scale in the channel. Partnerize offers an expansive partner ecosystem across Southeast Asia, including in the key Pomelo markets of Thailand, Indonesia, and Singapore.

“There is enormous potential for Pomelo within the channel, and we are thrilled to be working with them to enable this growth,” said Alix Simpson, VP of Customer Success, APAC, for Partnerize. “We look forward to working with this industry-leading merchant as it drives extraordinary growth across the region.”

About Partnerize
Partnerize is the leader in partnership automation. The AI-powered Partnerize Partner Automation Platform delivers data-driven intelligence and industry-leading management tools that are essential for materially improving ROI from this fast-growing sales channel. The Partnerize platform has won more than two dozen awards including Best Technology from the International Performance Marketing Awards. The world’s leading companies, including 63 top retailers, 12 international airlines, 9 of the largest telecoms, and more than 200 other global brands rely on Partnerize to drive and manage more than $6B in partner sales and $500M in partner payments every year. For more information on how Partnerize can grow your partnerships and business, please visit https://partnerize.com.

About Pomelo
Launched in 2013, Pomelo is an omnichannel fashion brand born in Asia with a global mindset: on-trend, online, on-the-go. With an undisputable sense of style at an unparalleled price, Pomelo’s ever-growing assortment continues to evolve with weekly new arrivals. All orders placed on POMELOFASHION.COM or the Pomelo Android and iOS App deliver worldwide, serving over 50 countries. Visit www.pomelofashion.com to discover more.

Bill Brazell
+1 917-445-7316

Pomelo เลือกใช้โซลูชัน ความร่วมมืออัตโนมัติของ Partnerize

ผู้ค้าปลีกสินค้าแฟชั่นออนไลน์ชั้นนำจะใช้แพลตฟอร์มของ Partnerize ในการบริหารความร่วมมือเพื่อสร้างรายได้ทั้งหมดในตลาดภูมิภาคเอเชียตะวันออกเฉียงใต้

กรุงเทพ, March 11, 2020 (GLOBE NEWSWIRE) — Partnerize ผู้นำด้านโซลูชันความร่วมมืออัตโนมัติสำหรับแบรนด์ระดับโลก ประกาศในวันนี้ว่า Pomelo แพลตฟอร์มสินค้าแฟชั่นออนไลน์ชั้นนำในเอเชียได้เลือกแพลตฟอร์มของ Partnerize เป็นโซลูชันความร่วมมืออัตโนมัติเพื่อเร่งการเติบโต แพลตฟอร์มความร่วมมืออัตโนมัติที่ประมวลผลด้วยปัญญาประดิษฐ์ (AI) ผสานรวมความรอบรู้ที่ขับเคลื่อนด้วยข้อมูลและเครื่องมือบริหารชั้นนำของอุตสาหกรรมที่จำเป็นเพื่อสร้างผลตอบแทนจากการลงทุน (ROI) สูงสุดจากความร่วมมือ

การตัดสินใจของ Pomelo ในการเลือก Partnerize เป็นส่วนหนึ่งของกลยุทธ์ที่มีวิสัยทัศน์ซึ่งผสานรวมเทคโนโลยีต่างๆ ที่เป็นนวัตกรรม ทำให้บริษัทแฟชั่นเทคโนโลยีแห่งนี้สามารถสร้างมุมมอง 360 รอบตัวลูกค้าและปรับปรุงกระบวนการทำงานให้ดีที่สุด นอกจากกลยุทธ์การจำหน่ายหลากหลายช่องทางแล้ว Pomelo ยังใช้เทคโนโลยีที่ดีที่สุดเพื่อสร้างประสบการณ์ที่ราบรื่นให้กับลูกค้าและรับทราบข้อมูลเชิงลึกทางธุรกิจ Pomelo จะใช้แพลตฟอร์มของ Partnerize เพื่อเพิ่มยอดขายที่ขับเคลื่อนโดยพาร์ทเนอร์ และขยายระบบนิเวศสำหรับความร่วมมือด้วยพาร์ทเนอร์ใหม่ๆ ที่สามารถช่วยขยายขนาดได้ดีเยี่ยม

“ที่ Pomelo เป้าหมายของเราคือการเชื่อมโยงประสบการณ์ออนไลน์และออฟไลน์ให้กับลูกค้าของเราอย่างราบรื่น” Jean Thomas ซีเอ็มโอของ Pomelo กล่าว “เรามั่นใจว่าแพลตฟอร์มของ Partnerize จะทำให้เราสามารถบรรลุเป้าหมายนี้ พร้อมช่วยให้เราสามารถเพิ่มผลลัพธ์ทางการตลาดอย่างมีประสิทธิภาพและขยายขนาดได้”

ปัจจัยหลักอย่างหนึ่งในการเลือกครั้งนี้ก็คือการผสานรวม Partnerize กับ Branch ซึ่งเป็นแพลตฟอร์มการเชื่อมโยงเชิงลึกและวัดผลผ่านมือถือ ยอดขายส่วนใหญ่ของ Pomelo เกิดขึ้นบนอุปกรณ์มือถือ การติดตามยอดขายบนอุปกรณ์มือถือและที่คล้ายกันอย่างครอบคลุมจึงเป็นองค์ประกอบที่จำเป็นของโปรแกรมทางการตลาดที่มีประสิทธิภาพ เพื่อให้แน่ใจว่าพาร์ทเนอร์แต่ละรายจะได้รับเครดิตจากการคอนเวอร์ชันทั้งหมดที่พาร์ทเนอร์ทำได้สำเร็จ

โดยการแต่งตั้ง Anders Heikenfeldt เป็นประธานคณะเจ้าหน้าที่ค้าปลีกเมื่อเร็วๆ นี้ Pomelo จะดำเนินการขยายการค้าปลีกทั่วทั้งเอเชียตะวันออกเฉียงใต้อย่างต่อเนื่อง บริษัทวางแผนที่จะใช้ระบบนิเวศขนาดใหญ่สำหรับพาร์ทเนอร์ของ Partnerize เพื่อเร่งการเติบโตและขยายขนาดในช่องทางการขาย Partnerize มีระบบนิเวศขนาดใหญ่สำหรับพาร์ทเนอร์ทั่วทั้งเอเชียตะวันออกเฉียงใต้ รวมทั้งตลาดหลักของ Pomelo ในประเทศไทย อินโดนีเซีย และสิงคโปร์

“มีศักยภาพขนาดมหึมาสำหรับ Pomelo ภายในช่องทางการขาย และเรารู้สึกตื่นเต้นที่จะได้ทำงานร่วมกับพวกเขาเพื่อสร้างการเติบโตนี้” Alix Simpson รองประธานฝ่าย Customer Success ประจำภูมิภาคเอเชียแปซิฟิกของ Partnerize กล่าว “เราตั้งตาคอยการทำงานกับผู้ค้าชั้นนำของอุตสาหกรรมเพื่อขับเคลื่อนการเติบโตแบบเกินคาดหมายทั่วทั้งภูมิภาค”

เกี่ยวกับ Partnerize
Partnerize คือผู้นำด้านความร่วมมืออัตโนมัติ แพลตฟอร์มความร่วมมืออัตโนมัติที่ประมวลผลด้วยปัญญาประดิษฐ์ (AI) ของ Partnerize มีความรอบรู้ที่ขับเคลื่อนด้วยข้อมูลและเครื่องมือบริหารชั้นนำของอุตสาหกรรมที่จำเป็นเพื่อเพิ่มผลตอบแทนจากการลงทุน (ROI) ให้มากยิ่งขึ้นจากช่องทางการขายที่เติบโตเร็ว แพลตฟอร์ม Partnerize ได้รับรางวัลมากกว่ายี่สิบสี่รางวัล รวมทั้งรางวัล Best Technology จากรายการ International Performance Marketing Awards บริษัทชั้นนำต่างๆ ของโลกซึ่งได้แก่ 63 ผู้ค้าปลีกระดับท็อป, 12 สายการบินระหว่างประเทศ, 9 บริษัทโทรคมนาคมที่ใหญ่ที่สุด และมากกว่า 200 แบรนด์ระดับโลกต่างเชื่อใจ Partnerize ในการขับเคลื่อนและบริหารยอดขายของพาร์ทเนอร์มากกว่า 6 พันล้านดอลลาร์และการชำระเงินให้พาร์ทเนอร์กว่า 500 ล้านดอลลาร์ทุกปี สำหรับข้อมูลเพิ่มเติมเกี่ยวกับวิธีการที่ Partnerize สามารถสร้างความร่วมมือและธุรกิจ โปรดเข้าไปที่ https://partnerize.com

เกี่ยวกับ Pomelo
เปิดตัวในปี 2013 Pomelo คือแบรนด์สินค้าแฟชั่นที่จำหน่ายหลากหลายช่องทางในเอเชียโดยมีวิสัยทัศน์ระดับโลกทั้งออนเทรนด์ ออนไลน์ ออนเดอะโก ด้วยสไตล์สร้างสรรค์และราคาที่ไม่มีใครเทียบได้ Pomelo มีสินค้าหลายประเภทและยังคงเพิ่มขึ้นอย่างต่อเนื่องด้วยสินค้ามาใหม่ทุกสัปดาห์ คำสั่งซื้อทั้งหมดบน POMELOFASHION.COM หรือแอป Pomelo ใน Android และ iOS จะส่งถึงคุณทั่วโลก พร้อมให้บริการในกว่า 50 ประเทศ ดูเพิ่มเติมได้ที่ www.pomelofashion.com

Bill Brazell
+1 917-445-7316